| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3277 | Md-39-am | Diuretic agent, impling an increase in the Na+ excretion and showing antihypertensive effect |
|
| DCC3278 | Mdc-1112 | Novel valproic acid (VPA) derivative, as a potent STAT3 inhibitor |
|
| DCC3279 | Mdcccl1636 | Novel partial PPARgamma ligand, displaying partial agonist activity in biochemical and cell-based transactivation assays, and reversed insulin resistance |
|
| DCC3280 | Mdctmp | Novel proteolysis-resistant self-localizing ligand (SL), sustaining PM localization of eDHFR-fusion proteins (over several hours to a day), inducing prolonged signal activation and cell differentiation |
|
| DCC3281 | Mde 6-82-1c | Novel MC5R antagonist |
|
| DCC3282 | Mde10-136rs | Novel potent and highly selective melanocortin-3 receptor (MC3R) agonist, showing greater than 140-fold selective for the mMC3R over the mMC4R, possessed 70 nM potency at the mMC3R, and partially stimulated the mMC4R at 100 μM concentrations without antag |
|
| DCC3283 | Mde6-5-2c | Novel potent and nonselective MC3R and MC4R macrocyclic agonist. decreased food intake and respiratory exchange ratio (RER) |
|
| DCC3284 | Mdg486 | Novel Inhibitor of BAF, activating latent HIV-1 |
|
| DCC3285 | mdg559 | Novel peroxisome proliferator activated receptor |
|
| DCC3286 | mdg582 | Novel peroxisome proliferator activated receptor γ (PPARγ) ligand |
|
| DCC3287 | Mdl100240 | Dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase |
|
| DCC3288 | Mdm2/x Pdi | Potent Peptide dual inhibitor of MDM2/X, inhibiting p53 interactions with MDM2 (IC50 = 10 nmol/L) and MDMX (IC50 = 100 nmol/L), inducing apoptosis and cell cycle arrest of cell lines with overexpressed MDM2/X |
|
| DCC3289 | Mdm2/xiap-in-14 | Novel potent dual MDM2/XIAP inhibitor |
|
| DCC3290 | Mdm2-p53-in-1b | Novel inhibitor of the MDM2-p53 interaction |
|
| DCC3291 | Mdmb-chminaca | Potent ligand of the central CB1 receptor |
|
| DCC3292 | Me1111 | Novel selective inhibitor of succinate dehydrogenase (complex II) of dermatophyte species |
|
| DCC3293 | me6tren Tetrahydrochloride | Potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs), activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD3100 |
|
| DCC3294 | Mebeverine Hydrochloride Featured | Second generation papaverine analog, acting as an anticholinergic agent |
|
| DCC3295 | Mebhydrolin | Selective FXR antagonist, ameliorates glucose homeostasis in type 2 diabetic mice |
|
| DCC3296 | Medermycin | Polyketide antibiotic, acting as a AKT selective kinase inhibitor, alkylating a regulatory loop cysteine |
|
| DCC3297 | Medrogestone | Progestational hormone, for the treatment of menstrual irregularities, prostatic hypertrophy, and endometrial carcinoma |
|
| DCC3298 | Me-indoxam | Potent sPLA2 inhibitor, having no effect on arachidonic acid release and platelet activating factor synthesis |
|
| DCC3299 | mel_s3 | Inducer of Megakaryocyte Differentiation in Erythroleukemia Cells, Impairing Bcr-Abl Signaling Cascades |
|
| DCC3300 | Melafolone | Natural dual inhibitor of COX-2 and EGFR, improving program death 1 (PD-1) checkpoint blockade therapy through normalizing tumor vasculature and PD-L1 downregulation |
|
| DCC3301 | Melarsoprol | Prodrug of melarsen oxide (Mel Ox), irreversibly binding to vicinal sulfhydryl groups on pyruvate kinase, disrupting energy production in the parasite |
|
| DCC3302 | Melinamide | Inhibitor of cholesterol esterification |
|
| DCC3303 | Melk-in-c1 | Novel Multi-Kinase Inhibitor, Triggering Mitotic Catastrophe of Glioma Stem Cells Mainly through MELK Kinase Inhibition |
|
| DCC3304 | Melogliptin | Potent, selective and orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4) |
|
| DCC3305 | Melperone Hydrochloride | 5-HT2A/D2 receptor antagonist |
|
| DCC3306 | Men16132 | Novel potent and selective nonpeptide kinin B2 receptor antagonist |
|
